Skip Ribbon Commands
Skip to main content
Menu

Publications

Prof N Gopalakrishna IYER

  1. Tan, D. S., Chong, F. T., Leong, H. Y., Toh, S. Y., Lau, D. H. W., Kwang, X. L., Zhang, X., Sundaram, G. M., Tan, G. S., Chang, M., Chua, B. Y., Lim, W., Tan, E. L., Ang, M., Li, H., Sampath, P., Chowbay, B., Skanderup, A. J., DasGupta, R., & Iyer, N. G. (2017). Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nature Medicine, 23(10), 1167–1175. https://doi.org/10.1038/nm.4401 
  2. Chia, S., Low, J., Zhang, X., Kwang, X. L., Chong, F. T., Sharma, A., Bertrand, D., Toh, S. Y., Leong, H. Y., Thangavelu, M. T., Hwang, J. S., Lim, K. H., Skanthakumar, T., Tan, H. K., Su, Y., Choo, S. H., Hentze, H., Tan, I. B., Lezhava, A., Tan, P., Tan, D.S, Periyasamy, G., Koh, J. L. Y., Iyer, N.G., & DasGupta, R. (2017). Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nature Communications, 8(1). https://doi.org/10.1038/s41467-017-00451-5 
  3. Iyer, N. G., Chin, S., Özdağ, H., Daigo, Y., Hu, D., Cariati, M., Brindle, K. M., Aparicio, S., & Caldas, C. (2004). p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proceedings of the National Academy of Sciences of the United States of America, 101(19), 7386–7391. https://doi.org/10.1073/pnas.0401002101 
  4. Rasheed, S. a. K., Leong, H. Y., Lakshmanan, M., Raju, A., Dadlani, D., Chong, F. T., Shannon, N. B., Rajarethinam, R., Skanthakumar, T., Tan, E. Y., Hwang, J. S., Lim, K. H., Tan, D. S., Ceppi, P., Wang, M. L., Tergaonkar, V., Casey, P. J., & Iyer, N. G. (2017). GNA13 expression promotes drug resistance and tumor-initiating phenotypes in squamous cell cancers. Oncogene, 37(10), 1340–1353. https://doi.org/10.1038/s41388-017-0038-6 
  5. Vettore, A. L., Ramnarayanan, K., Sepich-Poore, G. D., Lim, K. B. L., Ong, C. N., Srivastava, S., Leong, H. Y., Chong, F. T., Li, H., Lim, W. M., Cutcutache, I., Mcpherson, J. D., Suzuki, Y., Zhang, S., Skanthakumar, T., Wang, W., Tan, D. S., Cho, B. C., Teh, B. T., Rozen, S., Tan, P., & Iyer, N. G. (2015). Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Medicine, 7(1). https://doi.org/10.1186/s13073-015-0219-2 
  6. Iyer, N. G., Tan, D. S., Tan, V. K. M., Wang, W., Hwang, J. S., Tan, N. C., Sivanandan, R., Tan, H. K., Lim, W., Ang, M., Wee, J., Soo, K. C., & Tan, E. L. (2015). Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer, 121(10), 1599–1607. https://doi.org/10.1002/cncr.29251 
  7. Iyer, N. G., Morris, L. G. T., Tuttle, R. M., Shaha, A. R., & Ganly, I. (2011). Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer, 117(19), 4439–4446. https://doi.org/10.1002/cncr.26070 
  8. Zhao, Y. B., Ms, H., Leong, H. V., Lim, C., Pan, Y. B., Cheung, E., Soo, K. C., & Iyer, N. G. (2007). Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells. Oncogene, 27(1), 1–8. https://doi.org/10.1038/sj.onc.1210625 
  9. Wong, T. H., Skanthakumar, T., Nadkarni, N., Van Nguyen, H., & Iyer, N. G. (2017). Survival of patients with head and neck squamous cell carcinoma by housing subsidy in a tiered public housing system. Cancer, 123(11), 1998–2005. https://doi.org/10.1002/cncr.30557 
  10. Iyer, N. G., Xian, J., Chin, S. F., Bannister, A. J., Daigo, Y., Aparicio, S., Kouzarides, T., & Caldas, C. (2006). p300 is required for orderly G1/S transition in human cancer cells. Oncogene, 26(1), 21–29. https://doi.org/10.1038/sj.onc.1209771

Professor Pierce Chow

Selected publications of the last 5 years:

  1. Jeon AJ, Anene-Hzelu CG, Teo YY, Chong SL, Sekar K, Wu L, Chew SC, …., Foo RSY, Chow PKH. (2023) A genomic enhancer signature associates with hepatocellular carcinoma prognosis. J. Hep Reports, 5(6):100715. https://doi.org/10.1016/j.jhepr.2023.100715 
  2. Thng DKH, Hooi L, Toh CCM, Lim JJ, Rajagopalan D, Syariff IQC, Tan ZM, Rashid MBMA, Zhou L, Kow AWC, Bonney GK, Goh BKP, Kam JH, Jha S, Dan YY, Chow PKH, Toh TB, Chow EK (2023). Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer. Mol Oncol, https://doi.org/10.1002/1878-0261.13417 
  3. Jeon AJ, Teo YY, Sekar K, Chong SL, Wu L, Chew SC, Chen J, Kendarsari RI, Lai H, Ling WH, Kaya NA, Lim JQ, Ramasamy A, Oguz G, …, Goh BKP, Tucker-Kellogg G, Foo RSY, Chow PKH. (2023) Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma. BMC Cancer, 23(1):118. https://doi.org/10.1186/s12885-022-10444-3 
  4. Thng DKH, Toh TB, Pigini P, Hooi L, Dan YY, Chow PK, Bonney GK, Rashid MBMA, Guccione E, Wee DKB, Chow EK. (2022) Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma. Bioeng Transl Med, 8(1):e10363. https://doi.org/10.1002/btm2.10363 
  5. Lee YH, Chuah S, Nguyen PHD, Lim CJ, Lai HLH, Wasser M, …, Chow PKH, Albani S, Liu H, Chew V (2022) IFNγ-IL-17+ CD8 T cells contribute to immunosuppression and tumor progression in human hepatocellular carcinoma, Cancer Lett, 552:215977. https://doi.org/10.1016/j.canlet.2022.215977 
  6. Nguyen PHD, Ma S, Phua CZJ, Kaya NA, Lai HLH, Lim CJ, Lim JQ, Wasser M, Lai L, Tam WL, Lim TKH, Wan WK, Loh T, Leow WQ, Pang YH, Chan CY, Lee SY, Cheow PC, Toh HC, Ginhoux F, Iyer S, Kow AWC, Young Dan Y, Chung A, Goh BKP, Albani S, Chow PKH, Zhai W, Chew V. (2021) Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun., 12(1):227. https://doi.org/10.1038/s41467-020-20171-7. PMID: 33431814. 
  7. Chew XH, Sultana R, Mathew EN, Ng DCE, Lo RHG, Toh HC, Tai D, Choo SP, Goh BKP, Yan SX, Loke KSH, Thang SP, Gogna A, Venkatanarasimha NK, Tong AKT, Moe FNN, Chua JSS, Ang RWT, Ong AD, Ng AWY, Hoang MTQ, Too CW, Thng CH, Chan WY, Kee W, Chan JHM, Irani F, Leong S, Lim KH, Wang MLC, Chow PKH. (2021) Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma. Liver Cancer. https://doi.org/10.1159/000514400 
  8. Sharma A, Seow JJW, Dutertre CA, Pai R, Blériot C, Mishra A, Wong RMM, Singh GSN, Sudhagar S, Khalilnezhad S, Erdal S, Teo HM, Khalilnezhad A, Chakarov S, Lim TKH, Fui ACY, Chieh AKW, Chung CP, Bonney GK, Goh BK, Chan JKY, Chow PKH, Ginhoux F, DasGupta R. (2020) Onco-fetal Reprogramming of Endothelial Cells Drives Immunosuppressive Macrophages in Hepatocellular Carcinoma. Cell, 183(2):377-394.e21. https://doi.org/10.1016/j.cell.2020.08.040. PMID: 32976798 
  9. Ding, Z., Ericksen, R, Escande-Beillard, N., Lee, Q.Y, Loh A., Denil, S., Steckel, M., Andrea Haegebarth, A., Ho, S.W., Chow, P.K., Toh, H.C., Reversade, B., Gruenewald, S., Han, W. (2020) Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis. J. Hepatol., 72(4):725-35, ISSN 0168-8278, https://doi.org/10.1016/j.jhep.2019.10.026 
  10. Hack, S. P., Spahn, J., Chen, M., Cheng, A. L., Kaseb, A., Kudo, M., Lee, H. C., Yopp, A., Chow, P., & Qin, S. (2020). IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol., 16(15):975-89. https://doi.org/10.2217/fon-2020-0162 
  11. Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, Ding Z, Shuen T, Toh HC, Dan YY, Bonney GK, Zhou L, Chow P, Wang Y, Benoukraf T, Chow EK, Han W. (2020) Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression. Hepatol. Commun., 4(9):1362-81. https://doi.org/10.1002/hep4.1559. 
  12. Jin, Y., Wong, Y.S., Goh, B.K.P., Chan, C.Y., Cheow, P.C., Chow, P.K.H., Lim, T.K.H., Goh, G.B.B., Krishnamoorthy, T.L., Kumar, R., Ng, T.P., Chong, S.S., Tan, H.H., Chung, A.Y.F, Ooi, L.L., Chang, J.P.E., Tan, C.K., and Lee, C.G.L. (2019) Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma. Sci. Rep., 9(10464). https://doi.org/10.1038/s41598-019-46872-8 
  13. Chew, V., Lee, Y.H., Pan, L., Nasir, N.J.M., Lim, C.J., Chua, C., Lai, L., Hazirah, S.N., Lim, T.K.H., Goh, B.K.P., Chung, A., Lo, R.H.G., Ng, D., Filarca, R.L.F, Albani, S., and Chow, P.K.H. (2018). Immune Activation Underlies a Sustained Clinical Response to Yttrium-90 Radioembolisation in Hepatocellular Carcinoma. Gut. pii: gutjnl-2017-315485. https://doi.org/10.1136/gutjnl-2017-315485. 
  14. Lim, C.J., Lee, Y.H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T.K.H., Yeong, J., Toh, H.C., Lee, S.Y., Chan, C.Y., Goh, B.K., Chung, A., Heikenwalder, M., Ng, I.O., Chow, P., Albani, S., and Chew, V. (2018). Multidimensional Analyses Reveal Distinct Immune Microenvironment in Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut. https://doi.org/10.1136/gutjnl-2018-316510. 
  15. Zhao, Y., Shuen, T.W.H., Toh, T.B., Chan, X.Y., Liu, M., Tan, S.Y., Fan, Y., Yang, H., Lyer, S.G., Bonney, G.K., Loh, E., Chang, K.T.E., Tan, T.C., Zhai, W., Chan, J.K.Y., Chow, E.K., Chee, C.E., Lee, G.H., Dan, Y.Y., Chow, P.K., Toh, H.C., Lim, S.G., and Chen, Q. (2018). Development of a New Patient-Derived Xenograft Humanised Mouse Model to Study Human-Specific Tumour Microenvironment and Immunotherapy. Gut. pii: gutjnl-2017-315201. https://doi.org/10.1136/gutjnl-2017-315201. 
  16. Pierce K.H. Chow, Mihir Gandhi, Say-Beng Tan, et al. (2018) SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J. Clin. Oncol., JCO2017760892. https://doi.org/10.1200/JCO.2017.76.0892. 
  17. Zhai W, Lim TK, Zhang T, Phang ST, Tiang Z, Guan P, Ng MH, Lim JQ, Yao F, Li Z, Ng PY, Yan J, Goh BK, Chung AY, Choo SP, Khor CC, Soon WW, Sung KW, Foo RS, Chow PK (2017) The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8:4565. https://doi.org/10.1038/ncomms14565 
  18. Huynh, H., Lee, L.Y., Goh, K.Y., Ong, R., Hao, H.X., Huang, A., Wang, Y., Graus, P.D., Chow, P., and Chung, A. (2019). Infigratinib mediates vascular normalization, impairs metastasis, and improves chemotherapy in hepatocellular carcinoma. Hepatology 69(3):943-58. https://doi.org/10.1002/hep.30481. 
  19. Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, Lim KH, Weber A, Chow P, Chung A, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Chen Q, Abastado JP, Chew V (2017) Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut, 66(2):342-51. https://doi.org/1010.1136/gutjnl-2015-310814 
  20. Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V (2017) VESPRO: An Individual Patient Data Prospective Meta-Analysis of Selective Internal Radiation Therapy Versus Sorafenib for Advanced, Locally Advanced, or Recurrent Hepatocellular Carcinoma of the SARAH and SIRveNIB Trials. JMIR Res. Protoc. 6(2):17. https://doi.org/1010.2196/resprot.7016. 
  21. Gandhi M, Choo SP, Thng CH, Tan SB, Low AS, Cheow PC, Goh AS, Tay KH, Lo RH, Goh BK, Wong JS, Ng DC, Soo KC, Liew WM, Chow PK (2016) Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. BMC Cancer 16(1):856. https://doi.org/10.1186/s12885-016-2868-y

Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT)

  1. Tan JKT, Wong JSM, Seo CJ, Lim C, Zhu HY, Ong C-AJ, Chia CS (2023) Incidence and outcomes of delayed presentation and surgery in peritoneal surface malignancies. Front Oncol13: 1137785 
  2. Wong LCK*, Wong JSM*, Seo CJ, Soo KC, Ong C-AJ, Chia CS (2022) High intra-abdominal pressure during hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS) for peritoneal surface malignancies. Int J Hyperthermia39(1): 1195-1202 (* Equal contribution) 
  3. Zhao H, Pan S, Natalia A, Wu X, Ong C-AJ, Teo MCC, So JBY, Shao H (2023) A hydrogel-based mechanical metamaterial for the interferonic profiling of extracellular vesicles in patient samples. Nat Biomed Eng 7(2): 135-148 
  4. Wong JSM, Ng IAT, Juan WKD, Ong WS, Yang GM, Finkelstein EA, Gandhi M, Ong C-AJ, Seo CJ, Zhu H-Y, Chia CS (2022) Trajectories of patient-reported outcomes after palliative gastrointestinal surgery in advanced cancer. Is good quality of life sustainable? Ann Surg Open3(4): e206 
  5. Tan GHC, Chia CS, Wong JSM, Ong WS, Zhu H-Y, Ong C-AJ, Teo MCC (2023) Randomised controlled trial investigating perioperative immunoutrition for patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol30(2): 777-789 
  6. Chia CS, Wong LCK, Hennedige TP, Ong WS, Zhu H-Y, Tan GHC, Kwek JW, Seo CJ, Wong JSM, Ong C-AJ, Thng CH, Soo KC, Teo MCC (2022) Prospective comparison of the performance of MRI versus CT in the detection and evaluation of peritoneal surface malignancies. Cancers (Basel)14(13): 3179 
  7. Gwee YX, Chia DKA, So J, Yong WP, Tan P, Ong C-AJ*, Sundar R* (2022) Integration of genomic biology into therapeutic strategies of gastric cancer. J Clin Oncol40(24): 2830 (* Co-corresponding authors) 
  8. Hendrikson J*, Liu Y*, Ng WH, Lee JY, Lim AH, Loh JW, Ng CCY, Ong WS, Tan JWS, Tan QX, Ng G, Shannon NB, Lim WK, Lim TKH, Chua C, Wong JSM, Tan GHC, So JBY, Yeoh KG, Teh BT, Chia CS, Soo KC, Kon OL, Tan IBH, Chan JY, Teo MCC, Ong C-AJ, Singapore Peritoneal Oncology Study (SPOS) Group and Singapore Gastric Cancer Consortium (SGCC) (2022) Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. Cell Rep Med3(2): 100526 (* Equal contribution) 
  9. Wong JSM*, Lek SM*, Lim YZD, Chia CS, Tan GHC, Ong C-AJ, Teo MCC (2022) Palliative Gastro-intestinal Surgery in Patients with Advanced Peritoneal Carcinomatosis: Clinical Experience and Development of a Predictive Model for Surgical Outcomes. Front Oncol11: 811743 (* Equal contribution) 
  10. Yap DRY*, Wong JSM*, Tan QX, Tan JWS, Chia CS, Ong C-AJ (2021) Effect of HIPEC on peritoneal recurrence in peritoneal metastasis treated with cytoreductive surgery: a systematic review. Front Oncol11: 795390 (* Equal contribution) 
  11. Ong XYS, Sultana R, Tan JWS, Tan QX, Wong JSM, Chia CS, Ong CAJ (2021) The role of total parenteral nutrition in patients with peritoneal carcinomatosis: a systematic review and meta-analysis. Cancers (Basel) 13(16): 1456 
  12. Moon EW, Wong JSM, See AHM, Ong WS, Tan CA, Ong CAJ, Chia CS, Soo KC, Teo MCC, Tan GHC (2021) Predicting early and late readmissions following cytoreductive surgery & hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol28(11): 6613-6624 
  13. Shannon NB*, Tan QX*, Tan JWS, Hendrikson J, Ng WH, Ng G, Liu Y, Tan GHC, Wong JSM, Soo KC, Teo MCC, Chia CS, Ong CAJ (2021) Gene expression changes associated with dedifferentiation in liposarcoma predict overall survival. Cancers (Basel)13: 3049 (* Equal contribution) 
  14. Wang Z, Zhao H, Zhang Y, Natalia A, Ong CAJ, Teo MCC, So JBY, Shao H (2021) Surfactant-guided spatial assembly of nano-architecture for molecular profiling of extracellular vesicles. Nat Commun12(1): 4039 
  15. Chan J, Tan GF, Yeong J, Ong CW, Ng DYX, Lee E, Koh J, Ng CC-Y, Lee JY, Liu W, Wong RX, Ong C-AJ, Farid M, Teh BT, Soo KC (2021) Clinical implications of systemic and local immune responses in human angiosarcoma. npj Precision Oncology5(1):11 
  16. Thiagarajan S*, Tan JWS*, Zhou S, Tan QX, Hendrikson J, Ng WH, Ng G, Tan GHC, Soo KC, Teo MCC, Chia CS, Ong C-AJ (2021) Postoperative inflammatory marker surveillance in colorectal peritoneal carcinomatosis. Ann Surg Oncol 28(11): 6625-6635 
  17. Wu X, Zhao H, Natalia A, Lim CZJ, Ho NRY, Ong C-AJ, Teo MCC, So JBY, Shao H (2020) Exosome-templated nanoplasmonics for multiparametric molecular profiling. Sci Adv6(19): eaba2556

DSSO Breast Team:

  1. Tan SY, Tang MSS, Ong CJ, Tan VKM, Shannon NB. Impact of COVID-19 on Public Interest in Breast Cancer Screening and Related Symptoms: A Google Trends Analysis. JMIR Cancer. 2023 Jun 6;9:e39105. doi: 10.2196/39105. PMID: 37163461. 
  2. Tan HJ, Tan PH, Leong LCH, Tan VKM, Tan BKT, Lim SZ, Preetha M, Wong CY, Yong WS, Sim Y. Encapsulated papillary carcinoma of the breast: An institutional case series and literature review. Cancer Med. 2023 May;12(10):11408-11416. doi: 10.1002/cam4.5855. Epub 2023 Mar 31. PMID: 36999966. 
  3. Ho PJ, Khng AJ, Tan BKT, Tan EY, Lim GH, Tan SM, Tan VKM, Lim EH, Hartman M, Li J. Abstract P6-01-44: Alteration of DNA methylation landscape in breast patients treated with adjuvant chemotherapy. Cancer Res. 2023 Mar 1;83 (5_Suppl): P6-01-44. doi: 10.1158/1538-7445.SABCS22-P6-01-44. 
  4. Tan R, Ong WS, Lee KH, Park S, Iqbal J, Park YH, Lee JE, Yu JH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Koh J, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Yap YS. Abstract P3-05-36: Prognostic factors in non-metastatic hormone receptor-positive HER2-negative mucinous breast cancer: an international multicentre cohort study. Cancer Res. 2023 Mar 1;83(5_Suppl): P3-05-36. doi: 10.1158/1538-7445.SABCS22-P3-05-36. 
  5. Zhang Z, Ma J, Tan JYT, Ong WS, Kamis S, Yang G, Tan BKT, Tan VKM, Tan TJ. Abstract P4-07-49: Neoadjuvant therapy in Asian breast cancer patients with early & locally advanced breast cancers–A contemporary experience from a large tertiary hospital in Singapore. Cancer Res. 2023 Mar 1;83(5_Suppl):P4-07-49. doi: 10.1158/1538-7445.SABCS22-P4-07-49. 
  6. Ma J, Zhang Z, Tan JYT, Ong WS, Kamis S, Tan BKT, Tan VKM, Kanesvaran R, Tan TJY. Abstract P6-05-21: Quality of Life and Perspectives of Older Adults with Early & Locally Advanced Breast Cancers Undergoing Pre-operative Therapy. Cancer Res. 2023 Mar; 83(5_Suppl):P6-05-21. doi: 10.1158/1538-7445.SABCS22-P6-05-21. 
  7. Choo ALE, Sim LS, Sittampalam K, Tan WC, Tay AZE, Nadarajah R, Tan VKM, Sim Y. Breast metastasis from endometrial clear cell carcinoma: A case report and review of the literature. Front Oncol. 2023 Jan 25;12:1070744. doi: 10.3389/fonc.2022.1070744. PMID: 36761429; PMCID: PMC9905423. 
  8. Busmanis I, Leong L, Lee K, Lim SZ. A curious breast pseudomalignancy. Pathology. 2023 Feb; 55 (S52). doi: 10.1016/j.pathol.2022.12.165. 
  9. Ong SS, Xu J, Sim CK, Khng AJ, Ho PJ, Kwan PKW, Ravikrishnan A, Tan KB, Tan QT, Tan EY, Tan SM, Putti TC, Lim SH, Tang ELS, Nagarajan N, Karnani N, Li J, Hartman M. Profiling Microbial Communities in Idiopathic Granulomatous Mastitis. Int J Mol Sci. 2023 Jan 5;24(2):1042. doi: 10.3390/ijms24021042. PMID: 36674562; PMCID: PMC9863225. 
  10. Liow JJK, Lim ZL, Sim TMY, Ho PJ, Goh SA, Choy SD, Chew YJ, Tan BK, Tan VKM, Hartman M, McCrickerd K, Li J. “It Will Lead You to Make Better Decisions about Your Health”—A Focus Group and Survey Study on Women’s Attitudes towards Risk-Based Breast Cancer Screening and Personalised Risk Assessments. Curr Oncol. 2022 Nov 25;29(12):9181-9198. doi: 10.3390/curroncol29120719. PMID: 36547133; PMCID: PMC9776908. 
  11. Leong F, Kusumawidjaja G, Sultana R, Ishak HM, Wong FY, Tan VKM, Tan BKT, Sim Y, Lim GH; Lim SH, Tan SM, Ngaserin S. 54 (PB-054) Poster - Superior survival after breast conserving therapy versus mastectomy – a multicenter Asian cohort study of 3655 patients. Eur J Cancer. 2022 Nov; 175(Suppl 1):S18. doi: 10.1016/S0959-8049(22)01392-2 
  12. Liow MHL, Lim ZL, Ho PJ, Goh SA, Murali S, Tan BKT, Tan VKM, Hartman M, Li J, McCrickerd K. Attitudes and barriers to mammography screening in Singaporean women through the eyes of their adult children: A focus group study. SSM Qualitative Res Health. 2022 Sep; :100168. doi.org/10.1016/j.ssmqr.2022.100168. 
  13. Chan CW, Poh BR, Wong CY, Kwah RYC, Leong LCH. TB or not TB? The axillary lump question. Ann Acad Med Singap. 2022 Sep;51(9):589-590. doi: 10.47102/annals-acadmedsg.202298. PMID: 36189707. 
  14. Ho PJ, Khng AJ, Tan BK, Tan EY, Tan SM, Tan VKM, Lim GH, Aronson KJ, Chan TL, Choi JY, Dennis J, Ho WK, Hou MF, Ito H, Iwasaki M, John EM, Kang D, Kim SW, Kurian AW, Kwong A, Lophatananon A, Matsuo K, Mohd-Taib NA, Muir K, Murphy RA, Park SK, Shen CY, Shu XO, Teo SH, Wang Q, Yamaji T, Zheng W, Bolla MK, Dunning AM, Easton DF, Pharoah PDP, Hartman M, Li J. Relevance of the MHC region for breast cancer susceptibility in Asians. Breast Cancer. 2022 Sep;29(5):869-879. doi: 10.1007/s12282-022-01366-w. Epub 2022 May 11. PMID: 35543923; PMCID: PMC9385763. 
  15. Lim ZL, Ho PJ, Khng AJ, Yeoh YS, Ong ATW, Tan BKT, Tan EY, Tan SM, Lim GH, Lee JA, Tan VK, Hu J, Li J, Hartman M. Mammography screening is associated with more favourable breast cancer tumour characteristics and better overall survival: case-only analysis of 3739 Asian breast cancer patients. BMC Med. 2022 Aug 4;20(1):239. doi: 10.1186/s12916-022-02440-y. PMID: 35922814; PMCID: PMC9351273. 
  16. EJX Chong, MJ Wang, JY Lim, GS Shen, MJY Chow, KK Koh, AJS Lim, DZ Hong, JJQ Ting, A. Pisupati, BKY Lam, YT Ong, M. Chiam, S. Mason, LKR Krishna, SY Tan. Surgical portfolios: A systematic scoping review. Surg Pract Sci. 2022 Sep; 10:100107. doi:10.1016/j.sipas.2022.100107. 
  17. Chen RY, Goh RY, Leung HT, Cheng S, Tan VKM, Chia CLK, Goo JTT, Ong MW. Clinical Significance of Radiologically Detected Small Indeterminate Extra-Mammary Lesions in Breast Cancer Patients. Eur J Breast Health. 2022 Jul 1;18(3):252-257. doi: 10.4274/ejbh.galenos.2022.2022-1-2. PMID: 35855201; PMCID: PMC9255656. 
  18. Yap DWT, Tan NKW, Tan BKJ, Teo YH, Tan VKM, See A, Toh ST. The Association of Obstructive Sleep Apnea With Breast Cancer Incidence and Mortality: A Systematic Review and Meta-analysis. J Breast Cancer. 2022 Jun;25(3):149-163. doi: 10.4048/jbc.2022.25.e11. Epub 2022 Mar 10. PMID: 35380020; PMCID: PMC9250875. 
  19. Lim JSH, Sim Y, Ngeow J, Yuen J, Tan VKM, Tan BKT, Yong WS, Wong CY, Lim SZ, Hamzah JLB, Tan SY, Wong FY, Madhukumar P. Male breast cancer: a Singapore perspective. ANZ J Surg. 2022 Jun;92(6):1440-1446. doi: 10.1111/ans.17737. Epub 2022 Apr 25. PMID: 35470542. 
  20. Ong SS, Ho PJ, Khng AJ, Lim EH, Wong FY, Tan BK, Lim SH, Tan EY, Tan SM, Tan VKM, Dent R, Tan TJY, Ngeow J, Madhukumar P, Hamzah JLB, Sim Y, Lim GH, Pang JS, Alcantara VS, Chan PMY, Chen JJC, Kuah S, Seah JCM, Buhari SA, Tang SW, Ng CWQ, Li J, Hartman M. Association between Breast Cancer Polygenic Risk Score and Chemotherapy-Induced Febrile Neutropenia: Null Results. Cancers (Basel). 2022 May 31;14(11):2714. doi: 10.3390/cancers14112714. PMID: 35681694; PMCID: PMC9179461. 
  21. Yit LFN, Quek SZH, Wong FY, Tan PH, Tan B, Sim Y, Tan BF, Wong RX, Tan TJY. 203P Curative treatment outcomes in metaplastic breast cancer. Ann Oncol. 2022 May; 33(Suppl 3):S220 doi.org/10.1016/j.annonc.2022.03.222 
  22. Ang BH, Ho WK, Wijaya E, Kwan PY, Ng PS, Yoon SY, Hasan SN, Lim JMC, Hassan T, Tai MC, Allen J, Lee A, Taib NAM, Yip CH, Hartman M, Lim SH, Tan EY, Tan BKT, Tan SM, Tan VKM, Ho PJ, Khng AJ, Dunning AM, Li J, Easton DF, Antoniou AC, Teo SH. Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast Cancer. J Clin Oncol. 2022 May 10;40(14):1542-1551. doi: 10.1200/JCO.21.01647. Epub 2022 Feb 10. PMID: 35143328. 
  23. Lim JT, Koh JJE, Ho PJ, Liu J, Lim SH, Tan EY, Tan BKT, Tan VKM, Tan SM, Yong WS, Hartman M, Chen C. Impact of Subsidy on the Use of Personalized Medicine in Breast Cancer. Value Health Reg Issues. 2022 May;29:108-115. doi: 10.1016/j.vhri.2021.10.002. Epub 2022 Jan 29. PMID: 35104748. 
  24. Ng PS, Boonen RA, Wijaya E, Chong CE, Sharma M, Knaup S, Mariapun S, Ho WK, Lim J, Yoon SY, Mohd Taib NA, See MH, Li J, Lim SH, Tan EY, Tan BK, Tan SM, Tan VK, van Dam RM, Rahmat K, Yip CH, Carvalho S, Luccarini C, Baynes C, Dunning AM, Antoniou A, van Attikum H, Easton DF, Hartman M, Teo SH. Characterisation of protein-truncating and missense variants in PALB2 in 15 768 women from Malaysia and Singapore. J Med Genet. 2022 May;59(5):481-491. doi: 10.1136/jmedgenet-2020-107471. Epub 2021 Apr 2. PMID: 33811135. 
  25. Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL; JBCR; Ai3. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Breast Cancer Res Treat. 2022 May;193(1):121-138. doi: 10.1007/s10549-022-06521-7. Epub 2022 Mar 9. PMID: 35262831. 
  26. Ho PJ, Ho WK, Khng AJ, Yeoh YS, Tan BK, Tan EY, Lim GH, Tan SM, Tan VKM, Yip CH, Mohd-Taib NA, Wong FY, Lim EH, Ngeow J, Chay WY, Leong LCH, Yong WS, Seah CM, Tang SW, Ng CWQ, Yan Z, Lee JA, Rahmat K, Islam T, Hassan T, Tai MC, Khor CC, Yuan JM, Koh WP, Sim X, Dunning AM, Bolla MK, Antoniou AC, Teo SH, Li J, Hartman M. Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. BMC Med. 2022 Apr 26;20(1):150. doi: 10.1186/s12916-022-02334-z. PMID: 35468796; PMCID: PMC9040206. 
  27. Ng DYX, Li Z, Lee E, Kok JST, Lee JY, Koh J, Ng CC, Lim AH, Liu W, Ng SR, Lim KS, Huang XX, Hong JH, Guan P, Sim Y, Thike AA, Nasir NDM, Li S, Tan PH, Teh BT, Chan JY. Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor. NPJ Breast Cancer. 2022 Apr 1;8(1):44. doi: 10.1038/s41523-022-00413-1. PMID: 35365682; PMCID: PMC8975864. 
  28. Sim Y, Lim C, Phyu N, Tan KTB, Chew LST, Wong CY, Madhukumar P, Yong WS, Lim SZ, Hamzah JLB, Tan SY, Chay WY, Wong FY, Tan PH, Tan VK. The Impact of Statin Use and Breast Cancer Recurrence - A Retrospective Study in Singapore. Front Oncol. 2022 Mar 31;12:835320. doi: 10.3389/fonc.2022.835320. PMID: 35433431; PMCID: PMC9008885. 
  29. Lim ZL, Lim GH, Ho PJ, Khng AJ, Yeoh YS, Ong ATW, Tan BKT, Tan EY, Tan SM, Tan VK, Li J, Hartman M. Associations between Pre-Diagnostic Physical Activity with Breast Cancer Characteristics and Survival. Cancers (Basel). 2022 Mar 30;14(7):1756. doi: 10.3390/cancers14071756. PMID: 35406528; PMCID: PMC8997033. 
  30. Tan RSYC, Ong WS, Lee KH, Lim AH, Park S, Park YH, Lin CH, Lu YS, Ono M, Ueno T, Naito Y, Onishi T, Lim GH, Tan SM, Lee HB, Ryu HS, Han W, Tan VKM, Wong FY, Im SA, Tan PH, Chan JY, Yap YS. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Med. 2022 Mar 17;20(1):105. doi: 10.1186/s12916-022-02284-6. PMID: 35296300; PMCID: PMC8928638. 
  31. Ho WK, Tai MC, Dennis J, Shu X, Li J, Ho PJ, Millwood IY, Lin K, Jee YH, Lee SH, Mavaddat N, Bolla MK, Wang Q, Michailidou K, Long J, Wijaya EA, Hassan T, Rahmat K, Tan VKM, Tan BKT, Tan SM, Tan EY, Lim SH, Gao YT, Zheng Y, Kang D, Choi JY, Han W, Lee HB, Kubo M, Okada Y, Namba S; BioBank Japan Project, Park SK, Kim SW, Shen CY, Wu PE, Park B, Muir KR, Lophatananon A, Wu AH, Tseng CC, Matsuo K, Ito H, Kwong A, Chan TL, John EM, Kurian AW, Iwasaki M, Yamaji T, Kweon SS, Aronson KJ, Murphy RA, Koh WP, Khor CC, Yuan JM, Dorajoo R, Walters RG, Chen Z, Li L, Lv J, Jung KJ, Kraft P, Pharoah PDB, Dunning AM, Simard J, Shu XO, Yip CH, Taib NAM, Antoniou AC, Zheng W, Hartman M, Easton DF, Teo SH. Polygenic risk scores for prediction of breast cancer risk in Asian populations. Genet Med. 2022 Mar;24(3):586-600. doi: 10.1016/j.gim.2021.11.008. Epub 2021 Dec 15. PMID: 34906514; PMCID: PMC7612481. 
  32. Bong TSH, Tan JKT, Ho JTS, Tan PH, Lau WS, Tan TM, Wong JSL, Tan VKM, Tan BKT, Madhukumar P, Yong WS, Lim SZ, Wong CY, Ong KW, Sim Y. Atypical Ductal Hyperplasia of the Breast on Core Needle Biopsy: Risk of Malignant Upgrade on Surgical Excision. J Breast Cancer. 2022 Feb;25(1):37-48. doi: 10.4048/jbc.2022.25.e7. PMID: 35199500; PMCID: PMC8876544. 
  33. Chiam M, Ho CY, Quah E, Chua KZY, Ng CWH, Lim EG, Tan JRM, Wong RSM, Ong YT, Soong YL, Kwek JW, Yong WS, Loh KWJ, Lim C, Mason S, Krishna LKR. Changing self-concept in the time of COVID-19: a close look at physician reflections on social media. Philos Ethics Humanit Med. 2022 Jan 26;17(1):1. doi: 10.1186/s13010-021-00113-x. PMID: 35078488; PMCID: PMC8789479. 
  34. Linn YL, Tay TKY, Tan EH, Wong JSL, Madhukumar P. Breast metastasis presenting as swelling with calcification - A case report and review of the literature. Breast Dis. 2022;41(1):151-154. doi: 10.3233/BD-210035. PMID: 35068435.



SingHealth Updates for Healthcare Professionals

HealthXchange E-news Subscription

Health Buddy App

About NCCS
Patient Care
Research & Innovation
Education & Training
Careers
Giving
SingHealth
SingHealth Duke-NUS

​ 30 Hospital Boulevard, 168583  +65 6436 8000


Award1Award2Award3Award4Award5
Singapore Health Awards
© 2021 SingHealth Group. All Rights Reserved.
Best viewed on IE 11, Firefox 27, Chrome 22, and Safari 7 and above.